eligibility_summary
Eligible: adults ≥18 with histologically/cytologically confirmed locally advanced, recurrent, or metastatic cancer, ECOG 0–1, life expectancy >3 months, consent, adequate organ function. Exclude: unresolved >grade 1 toxicities (except alopecia, fatigue, grade 2 neuropathy), pregnancy/lactation/conception plans, symptomatic CNS mets, antibody/excipient allergy, severe rest dyspnea/O2 need, clinical study participation within 1 month.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06390774 (Phase I, open-label, China). Intervention: SSGJ-705, a bispecific monoclonal antibody (biologic) given IV (QW, Q2W, or Q3W) as monotherapy. Mechanism of action: dual targeting of PD-1 and HER2. • Anti–PD-1 arm: immune checkpoint blockade to restore/augment T‑cell activation and cytotoxicity by inhibiting PD-1 signaling on T cells. • Anti‑HER2 arm: binds HER2 (ERBB2) on tumor cells to direct activity toward HER2-expressing tumors. Targets/cells/pathways: PD-1/PD-L1 axis on T cells, HER2 receptor on tumor cells. Population: adults with advanced solid malignancies, expansion may include HER2-positive, PD-L1–high, and driver gene–negative NSCLC. Endpoints: safety, tolerability, PK, preliminary efficacy.